A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes

• Michelle J. Pena,

  Affiliation Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Andreas Heinzel,

  Affiliation emergentec biodevelopment GmbH, Vienna, Austria

  ⨯
• Georg Heinze,

  Affiliation Center For Medical Statistics, Informatics, And Intelligent Systems, Medical University of Vienna, Vienna, Austria

  ⨯
• Alaa Alkhalaf,

  Affiliations Diabetes Centre, Isala Clinics, Zwolle, The Netherlands, Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Stephan J. L. Bakker,

  Affiliation Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Tri Q. Nguyen,

  Affiliation Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

  ⨯
• Roel Goldschmeding,

  Affiliation Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

  ⨯
• Henk J. G. Bilo,

  Affiliations Diabetes Centre, Isala Clinics, Zwolle, The Netherlands, Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Paul Perco,

  Affiliation emergentec biodevelopment GmbH, Vienna, Austria

  ⨯
• Bernd Mayer,

  Affiliation emergentec biodevelopment GmbH, Vienna, Austria

  ⨯
• Dick de Zeeuw,

  Affiliation Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯
• Hiddo J. Lambers Heerspink

  * E-mail: h.j.lambers.heerspink@umcg.nl

  Affiliation Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

  ⨯